



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAY 2 2006

Alcon Laboratories, Inc.  
c/o Ms. Sherri Lakota  
Associate Director, Regulatory Affairs  
2501 Discovery Drive  
Suite 500  
Orlando, Florida 32826

Re: P970043/S22  
LADARVision® 4000 Excimer Laser System and the LADAR™6000 Excimer Laser  
System  
Filed: November 3, 2005  
Amended: January 31, February 27, March 17, and April 10, 2006

Dear Ms. Lakota:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement for the LADARVision® 4000 Excimer Laser System and the LADAR™6000 Excimer Laser System. These devices use a 6.5 mm optical zone and a 9.0 treatment zone and are indicated for wave-front-guided (WFG) CustomCornea® laser assisted in-situ keratomileusis (LASIK):

- for the reduction or elimination of mixed astigmatism 1.00 D to less than 5.00 D cycloplegic cylinder magnitude at the spectacle plane, which is greater than the sphere magnitude, and the cylinder and sphere have opposite signs;
- in patients 21 years of age or older; and,
- in patients with documented stability of refraction for the prior 12 months, as demonstrated by a change in sphere and cylinder of less than or equal to 0.50 D.

The PMA supplement is approved. You may begin commercial distribution of the device as modified in accordance with the conditions described below and in the "Conditions of Approval" (enclosed).

The sale, distribution, and use of these devices are restricted to prescription use in accordance with 21 CFR 801.109 within the meaning of section 520(e) of the Federal Food, Drug, and Cosmetic Act (the act) under the authority of section 515(d)(1)(B)(ii) of the act. FDA has also determined that, to ensure the safe and effective use of the device, the device is further restricted within the meaning of section 520(e) under the authority of section 515(d)(1)(B)(ii), (1) insofar

as the labeling specify the requirements that apply to the training of practitioners who may use the device as approved in this order and (2) insofar as the sale, distribution, and use must not violate sections 502(q) and (r) of the act.

The following restrictions on the use, labeling, promotion, and advertising of these devices are applicable to you, as well as any device purchasers and users:

1. Only practitioners who are experienced in the medical management and surgical treatment of the cornea, who have been trained in laser refractive surgery including laser system calibration and operation, may use the devices as approved in this order.
2. Prospective patients, as soon as they express an interest in wavefront-guided LASIK for mixed astigmatism and prior to undergoing surgery, must receive from the treatment provider the Patient Information Booklet (as described in your final submission to this PMA supplement).
3. Prior to undergoing surgery, prospective patients must be informed of the alternatives for correcting their mixed astigmatism including eyeglasses, contact lenses, and other refractive surgeries.
4. Comparison of the safety and effectiveness of this laser with any other method of refractive correction in the promotion and advertising materials is prohibited. This prohibition is based on the fact that the data submitted for PMA supplemental approval of the LADARVision® 4000 and the LADAR6000™ Excimer Laser Systems do not compare the clinical outcomes of these devices with any other method of refractive correction. Such comparisons of safety and effectiveness are misleading and would misbrand your laser in accordance with section 502(a) of the act. All promotion and advertising for these devices must include the following information on indications, risks and benefits:
  - a. Approval of the premarket approval application supplement is for the LADARVision® 4000 and the LADAR6000™ Excimer Laser Systems to perform wavefront-guided LASIK of mixed astigmatism 1.00 D to less than 5.00 D cycloplegic cylinder magnitude at the spectacle plane, which is greater than the sphere magnitude, and the cylinder and sphere have opposite signs, and in patients 21 years of age or older with a documented stability of refraction for the prior 12 months, as demonstrated by a change in sphere and cylinder of less than or equal to 0.50 D.
  - b. Wavefront-guided LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), conventional LASIK, and other refractive surgeries.

- c. Approval of the application is based on a clinical trial of 110 eyes. All eyes were evaluated for effectiveness with 100% accountability at 1, 3, and 6 months, and 98.2% accountability at 9 months.
- d. The studies found that of the 110 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at 6 months, 98.2% were corrected to 20/40 or better, 87.3 % were corrected to 20/25 or better, and 63.6% were corrected to 20/20 or better without spectacles or contact lenses.
- e. The study showed that of the 110 eyes available for safety analysis at 6 months, no eyes lost more than 2 lines of best corrected vision that can be obtained with spectacles (BSCVA) and none of the eyes had BSCVA worse than 20/40.
- f. The clinical trials showed that the following adverse events or complications occurred in at least 1% of the 110 eyes at any post-treatment visit: grade  $\geq$  I superficial punctate keratitis (SPK) (10.0%), epithelium in the interface (5.4%), diffuse lamellar keratitis (DLK) in the operative eye (4.5%), pain at one month or later (1.8%), and miscreated flap (related to the microkeratome) (1.8%).
- g. The following subjective patient symptoms were rated “significantly worse” in the postoperative uncorrected state relative to the preoperative spectacle-corrected state in more than 1% of eyes at 6 months: blurring of vision (8.2%), fluctuation of vision (4.5%), halos (3.6%), night driving difficulty (3.6%), dryness (2.7%), light sensitivity (1.8%), and double vision (1.8%).
- h. The safety and effectiveness of wavefront-guided LASIK surgery for mixed astigmatism has ONLY been established with an optical zone 6.5 mm and an ablation zone of 9.0 mm.
- i. Long term risks of wavefront-guided LASIK treatment of mixed astigmatism beyond 9 months have not been studied.
- j. The safety and effectiveness of LADARVision<sup>®</sup> 4000 and LADAR6000<sup>™</sup> Excimer Laser Systems have NOT been established for wavefront-guided surgery in patients: whose wavefront diameter is less than 6.50 mm; for treatments of mixed astigmatism with 5.00 D or greater cycloplegic cylinder magnitude at the spectacle plane; and for retreatment.
- k. Although the LADARWave<sup>®</sup> CustomCornea<sup>®</sup> WaveFront System measures the refractive error and wavefront aberrations of the human eyes, including myopia, hyperopia, astigmatism, coma, spherical aberration, trefoil, and other higher order aberrations through sixth order, in the clinical study for this PMA, the average higher order aberration did not decrease after CustomCornea<sup>®</sup> treatment.

1. Note that the complete name for this ophthalmic laser is LADARVision®4000 and LADAR6000™ Excimer Laser Systems for the Wavefront-guided (WFG) Laser-Assisted in situ Keratomileusis (LASIK) treatment for the reduction or elimination of mixed astigmatism 1.00 D to less than 5.00 D cycloplegic cylinder magnitude at the spectacle plane, which is greater than the sphere magnitude, and the cylinder and sphere have opposite signs. An acceptable alternate version of this official name is “wavefront-guided LASIK for correction of mixed astigmatism”.

In addition to the postapproval requirements outlined in the enclosure, you must report to FDA CDRH's Office of Compliance at the address below of any instances of device tampering or usage outside of the approved indications, and any excimer systems that were exported under an 801(e) order and are now back in the U.S.

OC/Division of Enforcement (HFZ-331)  
Center for Devices and Radiological Health  
Food and Drug Administration  
2098 Gaither Road  
Rockville, MD 20850

CDRH does not evaluate information related to contract liability warranties, however you should be aware that any such warranty statements must be truthful, accurate, and not misleading, and must be consistent with applicable Federal and State laws.

CDRH will notify the public of its decision to approve your PMA by making available a summary of the safety and effectiveness data upon which the approval is based. The information can be found on the FDA CDRH Internet HomePage located at <http://www.fda.gov/cdrh/pmapage.html>. Written requests for this information can also be made to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any interested person may seek review of this decision by requesting an opportunity for administrative review, either through a hearing or review by an independent advisory committee, under section 515(g) of the Federal Food, Drug, and Cosmetic Act (the act).

Failure to comply with any postapproval requirement constitutes a ground for withdrawal of approval of a PMA. Commercial distribution of a device that is not in compliance with these conditions is a violation of the act.

You are reminded that, as soon as possible and before commercial distribution of your devices, you must submit an amendment to this PMA submission with copies of all approved labeling affected by this supplement in final printed form. The labeling will not routinely be reviewed by FDA staff when PMA supplement applicants include with their submission of the final printed


labeling a cover letter stating that the final printed labeling is identical to the labeling approved in draft form. If the final printed labeling is not identical, any changes from the final draft labeling should be highlighted and explained in the amendment.

All required documents should be submitted in triplicate, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing.

PMA Document Mail Center (HFZ-401)  
Center for Devices and Radiological Health  
Food and Drug Administration  
9200 Corporate Blvd.  
Rockville, Maryland 20850

If you have any questions concerning this approval order, please contact Daryl L. Kaufman at (301) 594- 2018.

Sincerely yours,

  
for Malvina B. Eydelman, M.D.  
Director

Division of Ophthalmic and Ear,  
Nose and Throat Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure  
Conditions of Approval

## CONDITIONS OF APPROVAL

**PREMARKET APPROVAL APPLICATION (PMA) SUPPLEMENT.** Before making any change affecting the safety or effectiveness of the device, submit a PMA supplement for review and approval by FDA unless the change is of a type for which a "Special PMA Supplement-Changes Being Effected" is permitted under 21 CFR 814.39(d) or an alternate submission is permitted in accordance with 21 CFR 814.39(e) or (f). A PMA supplement or alternate submission shall comply with applicable requirements under 21 CFR 814.39 of the final rule for Premarket Approval of Medical Devices.

All situations that require a PMA supplement cannot be briefly summarized; therefore, please consult the PMA regulation for further guidance. The guidance provided below is only for several key instances.

A PMA supplement must be submitted when unanticipated adverse effects, increases in the incidence of anticipated adverse effects, or device failures necessitate a labeling, manufacturing, or device modification.

A PMA supplement must be submitted if the device is to be modified and the modified device should be subjected to animal or laboratory or clinical testing designed to determine if the modified device remains safe and effective.

A "Special PMA Supplement - Changes Being Effected" is limited to the labeling, quality control and manufacturing process changes specified under 21 CFR 814.39(d)(2). It allows for the addition of, but not the replacement of previously approved, quality control specifications and test methods. These changes may be implemented before FDA approval upon acknowledgment by FDA that the submission is being processed as a "Special PMA Supplement - Changes Being Effected." This procedure is not applicable to changes in device design, composition, specifications, circuitry, software or energy source.

Alternate submissions permitted under 21 CFR 814.39(e) apply to changes that otherwise require approval of a PMA supplement before implementation of the change and include the use of a 30-day PMA supplement or annual postapproval report (see below). FDA must have previously indicated in an advisory opinion to the affected industry or in correspondence with the applicant that the alternate submission is permitted for the change. Before such can occur, FDA and the PMA applicant(s) involved must agree upon any needed testing protocol, test results, reporting format, information to be reported, and the alternate submission to be used.

Alternate submissions permitted under 21 CFR 814.39(f) for manufacturing process changes include the use of a 30-day Notice. The manufacturer may distribute the device 30 days after the date on which the FDA receives the 30-day Notice, unless the FDA notifies the applicant within 30 days from receipt of the notice that the notice is not adequate.

**POSTAPPROVAL REPORTS.** Continued approval of this PMA is contingent upon the submission of postapproval reports required under 21 CFR 814.84 at intervals of 1 year from the date of approval of the original PMA. Postapproval reports for supplements approved under the original PMA, if applicable, are to be included in the next and subsequent annual reports for the original PMA unless specified otherwise in the approval order for the PMA supplement. Two copies identified as "Annual Report" and bearing the applicable PMA reference number are to be submitted to the PMA Document Mail Center (HFZ-401), Center for Devices and Radiological Health, Food and Drug Administration, 9200 Corporate Blvd., Rockville, Maryland 20850. The postapproval report shall indicate the beginning and ending date of the period covered by the report and shall include the following information required by 21 CFR 814.84:

1. Identification of changes described in 21 CFR 814.39(a) and changes required to be reported to FDA under 21 CFR 814.39(b).
2. Bibliography and summary of the following information not previously submitted as part of the PMA and that is known to or reasonably should be known to the applicant:
  - a. unpublished reports of data from any clinical investigations or nonclinical laboratory studies involving the device or related devices ("related" devices include devices which are the same or substantially similar to the applicant's device); and
  - b. reports in the scientific literature concerning the device.

If, after reviewing the bibliography and summary, FDA concludes that agency review of one or more of the above reports is required, the applicant shall submit two copies of each identified report when so notified by FDA.

**ADVERSE REACTION AND DEVICE DEFECT REPORTING.** As provided by 21 CFR 814.82(a)(9), FDA has determined that in order to provide continued reasonable assurance of the safety and effectiveness of the device, the applicant shall submit 3 copies of a written report identified, as applicable, as an "Adverse Reaction Report" or "Device Defect Report" to the PMA Document Mail Center (HFZ-401), Center for Devices and Radiological Health, Food and Drug Administration, 9200 Corporate Blvd., Rockville, Maryland 20850 within 10 days after the applicant receives or has knowledge of information concerning:

1. A mix-up of the device or its labeling with another article.
2. Any adverse reaction, side effect, injury, toxicity, or sensitivity reaction that is attributable to the device and:
  - a. has not been addressed by the device's labeling; or
  - b. has been addressed by the device's labeling but is occurring with unexpected severity or frequency.

3. Any significant chemical, physical or other change or deterioration in the device, or any failure of the device to meet the specifications established in the approved PMA that could not cause or contribute to death or serious injury but are not correctable by adjustments or other maintenance procedures described in the approved labeling. The report shall include a discussion of the applicant's assessment of the change, deterioration or failure and any proposed or implemented corrective action by the applicant. When such events are correctable by adjustments or other maintenance procedures described in the approved labeling, all such events known to the applicant shall be included in the Annual Report described under "Postapproval Reports" above unless specified otherwise in the conditions of approval to this PMA. This postapproval report shall appropriately categorize these events and include the number of reported and otherwise known instances of each category during the reporting period. Additional information regarding the events discussed above shall be submitted by the applicant when determined by FDA to be necessary to provide continued reasonable assurance of the safety and effectiveness of the device for its intended use.

#### **REPORTING UNDER THE MEDICAL DEVICE REPORTING (MDR) REGULATION.**

The Medical Device Reporting (MDR) Regulation became effective on December 13, 1984. This regulation was replaced by the reporting requirements of the Safe Medical Devices Act of 1990 which became effective July 31, 1996 and requires that all manufacturers and importers of medical devices, including in vitro diagnostic devices, report to the FDA whenever they receive or otherwise become aware of information, from any source, that reasonably suggests that a device marketed by the manufacturer or importer:

1. May have caused or contributed to a death or serious injury; or
2. Has malfunctioned and such device or similar device marketed by the manufacturer or importer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

The same events subject to reporting under the MDR Regulation may also be subject to the above "Adverse Reaction and Device Defect Reporting" requirements in the "Conditions of Approval" for this PMA. FDA has determined that such duplicative reporting is unnecessary. Whenever an event involving a device is subject to reporting under both the MDR Regulation and the "Conditions of Approval" for a PMA, the manufacturer shall submit the appropriate reports required by the MDR Regulation within the time frames as identified in 21 CFR 803.10(c) using FDA Form 3500A, i.e., 30 days after becoming aware of a reportable death, serious injury, or malfunction as described in 21 CFR 803.50 and 21 CFR 803.52 and 5 days after becoming aware that a reportable MDR event requires remedial action to prevent an unreasonable risk of substantial harm to the public health. The manufacturer is responsible for submitting a baseline report on FDA Form 3417 for a device when the device model is first reported under 21 CFR 803.50. This baseline report is to include the PMA reference number. Any written report and its envelope is to be specifically identified, e.g., "Manufacturer Report," "5-Day Report," "Baseline Report," etc.



Any written report is to be submitted to:

Food and Drug Administration  
Center for Devices and Radiological Health  
Medical Device Reporting  
PO Box 3002  
Rockville, Maryland 20847-3002

Copies of the MDR Regulation (FOD # 336&1336) and FDA publications entitled "An Overview of the Medical Device Reporting Regulation" (FOD # 509) and "Medical Device Reporting for Manufacturers" (FOD #987) are available on the CDRH WWW Home Page. They are also available through CDRH's Fact-On-Demand (F-O-D) at 800-899-0381. Written requests for information can be made by sending a facsimile to CDRH's Division of Small Manufacturers International and Consumer Assistance (DSMICA) at 301-443-8818.